Perinatal presepsin assessment: a new sepsis diagnostic tool?
Author:
Botondi Valentina1, D’Adamo Ebe1, Plebani Mario2ORCID, Trubiani Oriana3, Perrotta Marika1, Di Ricco Laura1, Spagnuolo Cynzia1, De Sanctis Sara1, Barbante Elisabetta1, Strozzi Maria Chiara4, Maconi Antonio4, Gazzolo Francesca5, Betti Marta4, Roveta Annalisa4ORCID, Levantini Gabriella1, Gazzolo Diego1
Affiliation:
1. Neonatal Intensive Care Unit , G. D’Annunzio University , Chieti , Italy 2. Department of Laboratory Medicine , University Hospital of Padova , Padova , Italy 3. Department of Innovative Technologies in Medicine & Dentistry , University “G. D’Annunzio” , Chieti , Italy 4. AO SS Antonio, Biagio and C. Arrigo Hospital , Alessandria , Italy 5. Magna Graecia University , Catanzaro , Italy
Abstract
Abstract
Perinatal sepsis constitutes a medical emergency and is still one of the major causes of mortality and morbidity. The possibility of an early diagnosis of sepsis is still debated and controversial. In particular, clinical symptoms can be hidden by the association of sepsis with other perinatal diseases and/or by therapeutic strategies performed. In this context, there is evidence that the accuracy of standard of care diagnostic parameters (i.e. blood culture, C-reactive protein, procalcitonin) can be biased by additional confounding factors (gestational age, birth-weight, acute-chronic hypoxia). Therefore, the inclusion in clinical daily practice of new biomarkers of sepsis is of utmost importance. Of a panel of biomarkers, Presepsin (P-SEP) plays an important role in the development and response of the immune system and as an early marker of sepsis both in adult and pediatric patients. Therefore, in the present review we aim to offer an overview of the role of P-SEP in the early detection of perinatal sepsis as a trustworthy marker according to actual statements of official international institutions. Future perspectives regard the possibility of a longitudinal non-invasive biological fluids P-SEP assessment thus limiting the sample stress in high risk newborns.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference50 articles.
1. Chen, L, Xiao, T, Luo, Y, Qiu, Q, Que, R, Huang, X, et al.. Soluble CD14 subtype (sCD14-ST) is a biomarker for neonatal sepsis. Int J Clin Exp Pathol 2017;10:9718–24. 2. Gad, GI, Shinkar, DM, Kamel El-Din, MM, Nagi, HM. The utility of soluble CD14 subtype in early diagnosis of culture-proven early-onset neonatal sepsis and prediction of outcome. Am J Perinatol 2020;37:497–502. https://doi.org/10.1055/s-0039-1683863. 3. Singh, M, Alsaleem, M, Gray, CP. Neonatal sepsis. Treasure Island (FL): StatPearls; 2021. 4. Ahmed, AM, Mohammed, AT, Bastawy, S, Attalla, HA, Yousef, A, Abdelrazek, MS, et al.. Serum biomarkers for the early detection of the early-onset neonatal sepsis: a single-center prospective study. Adv Neonatal Care 2019;19:E26–32. https://doi.org/10.1097/anc.0000000000000631. 5. Shah, BA, Padbury, JF. Neonatal sepsis: an old problem with new insights. Virulence 2014;5:170–8. https://doi.org/10.4161/viru.26906.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|